Israeli Stocks: Ampal-American, Fibrolan, Given, Orckit, Teva

Israel’s TA-25 Index dropped for the first time this week, slipping 0.1 percent to 1,321.85 at the 4:30 p.m. close in Tel Aviv. Investors traded about 2.19 billion shekels ($596.3 million) in shares and convertible securities.

The following stocks rose or fell today. Symbols are in parentheses.

Ampal-American Israel Corp. (AMPL IT) climbed the most in three weeks, increasing 3.9 percent to 8.012 shekels. The holding company that owns 12.5 percent of East Mediterranean Gas Co. said gas supply to EMG is expected to resume by Feb. 17.

Fibrolan Ltd. (FIBR IT) gained the most since Nov. 24, advancing 6.6 percent to 3.569 shekels. The manufacturer of broadband access systems said its contract with Nokia Siemens Networks Australia has been extended through 2013.

Given Imaging Ltd. (GIVN IT) rose to the highest level since Sept. 21, increasing 2.1 percent to 67.96 shekels. The maker of capsule-sized cameras for diagnosing digestive ailments said its PillCam Colon capsule endoscopy is now reimbursable for inpatient use in German hospitals.

Orckit Communications Ltd. (ORCT IT) climbed to the highest since Jan. 23, gaining 4.3 percent to 10.66 shekels. The Israeli maker of telecommunications equipment said Cegecom SA, a Luxembourg regional telecommunication service provider, has chosen its CM-4000 PTN products.

Teva Pharmaceutical Industries Ltd. (TEVA IT) slid the most since July 25, retreating 4.3 percent to 192.10 shekels. The world’s biggest generic-drugmaker forecast 2011 earnings of $4.90 to $5.20 a share, below the $5.29 average estimate of 23 analysts compiled by Bloomberg. Fourth-quarter profit of $1.25 a share missed the average estimate of $1.28 a share from 21 analysts surveyed by Bloomberg in the past month.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.